Enumeral Biomedical Holdings Inc

Enumeral Biomedical — BiopharmAmerica 2015

19 slides from Enumeral Biomedical's conference presentation, Sep 17, 2015

  1. Slide 1: BiopharmAmerica 2015

    BiopharmAmerica 2015 September 17, 2015

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUC

  3. Slide 3: Enumeral Mission

    EnumeralMission 3 A biopharma company developing potential ‘best- in-class’ antibodies against both proven and new targets using a proprietary immuno-oncology profiling technology.

  4. Slide 4: Enumeral's Differentiated Approach

    Enumeral’sDifferentiated Approach 4 Create broad antibody diversity Measure antibody function using our ‘Human immune system on a chip’ platform Select best-in-class candidates that modulate desired immune effector cells

  5. Slide 5: Discovery and Profiling Processes

    Discovery and Profiling Processes 5

  6. Slide 6: Enumeral Platform

    EnumeralPlatform 6 Microwell device with 84,672 50m wells

  7. Slide 7: Platform Enables All IO Entry Points

    Platform Enables All IO Entry Points 7

  8. Slide 8: Functional Diversity: Potential for Best-in-Class Pharmacologic and MOA Differentiation

    Functional Diversity: Potential for Best-in-Class Pharmacologic and MOA Differentiation 8 Screen 1-12 Heavy chain AA sequences from PD1 N= 159 sequences shown; 28 families of antibodies OPDIVO® KEYTRUDA® Pidilizumab • 6 antibodies (from different clades) chosen for small scale production • Ability t

  9. Slide 9: Differential T-Cell Activation

    Differential T-Cell Activation 9 0 10 20 30 40 50 60 70 80 % P o s i t i v e C e l l s CD8+ IFN?+ CD4+ IFN?+ CD8+ TNFa+

  10. Slide 10: Antigen Recall Assay

    ~ Antigen Recall Assay ~ 7000 D4- HC3+LC1 a -= D4-HC1+LC3 —« D4-HC3+LC3 6000 —- C8-HC1+LC1 -e C8-HC1+LC3 -= C8-HC2+LC1 == 5000 Isotype Control 5000 E Nivolumab 25001 NN o4 0.001 0.01 0.1 1 10 100 Antibody Concentration (11.g/mL) IFNy (pg/ml) ENUSERAL

  11. Slide 11: Mixed Lymphocyte Reaction (6 days)

    Mixed Lymphocyte Reaction (6 days) 11

  12. Slide 12: Consistent, repeatable diversity for additional checkpoint targets

    Our approach to discovery has resulted in consistent, repeatable levels of diversity for additional checkpoint targets 12

  13. Slide 13: TIM-3 Program Diversity

    13 TIM-3 Program Diversity • CDR3 cladistics • 114 sequences • Greenboxes indicate a confirmed binder (ELISA) *indicates confirmed cell- based binder * * Screen1: 100600-100605 Screen4: 100646-100671 Screen6: 100730-100734 Screen12: 100810-100816 Screen13: 100874-100881 Screen14: 100928-100931 Scree

  14. Slide 14: LAG-3 Program Diversity

    14 LAG-3 Program Diversity • CDR3 cladistics shown • 64 sequences CONFIDENTIAL

  15. Slide 15: Why Diversity Matters

    Why Diversity Matters: • TIM-3 biology much more complex than any other I/O target: – Ligands: – Galectin-9 – Phosphatidylserine – CEACAM1 • Correct epitope is unknown for therapeutic TIM-3 blockade • TIM-3 also a marker for cancer progression 15 Anderson et al 2007 Immunity

  16. Slide 16: Tissue Profiling: Human Translational Link Between Discovery and Development

    Tissue Profiling: Human Translational Link Between Discovery and Development 16 Use of human tissues serves as a bridge between mAbfunction in vitro and cellular function in tumors in relevant indications

  17. Slide 17: Tumor Profiling at the Single Cell Level

    Tumor Profiling at the Single Cell Level 17

  18. Slide 18: Indication Mapping - TIM3

    O v a r i a n R e n a l C a n c e r A v a s t i n R a f / M E K i PD1 Blockade Indication Mapping  - T I M 3

  19. Slide 19: Conclusions

    Conclusions • Our PD1 program gives us an independent benchmark therapeuticfor partnering in immuno-oncology • Our pipeline places us in an ideal position to further combination IO strategies in diverse indications with urgent unmet need • Our single-cell analysis platform will allow us to better un

Enumeral Biomedical Holdings — BiopharmAmerica 2015 on 6ix